Compare TV & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TV | NUVB |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | Mexico | United States |
| Employees | 26599 | 307 |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | TV | NUVB |
|---|---|---|
| Price | $2.69 | $6.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $5.30 | ★ $11.38 |
| AVG Volume (30 Days) | 1.0M | ★ 4.3M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | N/A | $58.18 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $1.87 |
| 52 Week High | $3.49 | $9.75 |
| Indicator | TV | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 77.02 |
| Support Level | $2.61 | $4.13 |
| Resistance Level | $2.95 | $8.95 |
| Average True Range (ATR) | 0.11 | 0.41 |
| MACD | -0.00 | 0.16 |
| Stochastic Oscillator | 22.45 | 98.87 |
Televisa is one of the leading telecom firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with nearly 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 4 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in the combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.